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Abstract: Friedreich’s ataxia (FRDA) is an autosomal recessive disease caused by an abnormally
expanded Guanine-Adenine-Adenine (GAA) repeat sequence within the first intron of the frataxin
gene (FXN). The molecular mechanisms associated with FRDA are still poorly understood and most
studies on FXN gene regulation have been focused on the region around the minimal promoter and
the region in which triplet expansion occurs. Nevertheless, since there could be more epigenetic
changes involved in the reduced levels of FXN transcripts, the aim of this study was to obtain a more
detailed view of the possible regulatory elements by analyzing data from ENCODE and Roadmap
consortia databases. This bioinformatic analysis indicated new putative regulatory regions within the
FXN genomic locus, including exons, introns, and upstream and downstream regions. Moreover, the
region next to the end of intron 4 is of special interest, since the enhancer signals in FRDA-affected
tissues are weak or absent in this region, whilst they are strong in the rest of the analyzed tissues.
Therefore, these results suggest that there could be a direct relationship between the absence of
enhancer sequences in this specific region and their predisposition to be affected in this pathology.
Keywords: frataxin; Friedreich’s ataxia; histone modification; epigenetic regulation and BACs
1. Background
Friedreich’s ataxia (FRDA, [OMIM229300]), the most common form of hereditary ataxia among
individuals of Indo-European origin, is an autosomal recessive disease clinically characterized by progressive
cerebellum and spinal cord neurodegeneration, hypertrophic cardiomyopathy, and predisposition to
diabetes [1,2]. The disease has a prevalence of approximately 1 in 50,000 people in European populations [3],
with an early onset between 10 and 15 years, and most patients normally become wheelchair users around
15 years after the beginning of the symptoms [4].
FRDA, firstly described by physician Nicolas Friedreich in 1863, is caused by mutations in the
FXN gene [MIM 606829], which encodes for a protein called frataxin. The genetic defect associated
with the disease is mostly an abnormally expanded GAA repeat sequence within the first intron of
the gene [5]. Most FRDA patients (approximately 95%) are homozygous for the expansion and only
the remaining 5% are compound heterozygous for the expansion in one allele and generally a point
mutation in the other. It has been described that normal alleles contain 8–65 triplets, whereas patient’s
alleles typically contain up to 1700 repeats, with a direct correlation between the number of repeats
and the severity of the disease [6].
At the molecular level, the final consequence of GAA expansion is that FRDA patient cells
show a severe deficiency in frataxin transcription [5]; this ultimately leads to a shortage of frataxin,
which is a protein that plays an important role in Fe-S cluster biogenesis and in mitochondrial iron
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metabolism [7]. Frataxin is a mainly mitochondrial protein encoded by a nuclear gene located in the
long arm of chromosome 9 (9q21.11), which undergoes two proteolytic cleavages upon entry into the
mitochondria [8]. Although at low levels, the mature protein is ubiquitously expressed in healthy
individuals, being slightly higher in the dorsal root ganglia, the cerebellum granular layer and tissues
with great metabolic demand, such as in the heart and liver [4]. On the other hand, it should be noted
that frataxin overexpression is cytotoxic, and thus it requires a tight control of its expression [9]. In fact,
it has been proved that iron depletion causes a reduction of frataxin mRNA levels in both control and
FRDA-derived patient cells, presumably indicating a negative feedback mechanism between disease
phenotype and protein expression [10]. The mature protein is translated from the main transcript
(FXN I), although two minority transcripts produced by the alternative splicing of exon 4 have also
been described [11], containing exon 5b instead of exon 5a, with or without noncoding exon 6 [5];
however, few data support their implication in the disease. Recently, two new isoforms of the protein
have been described, with both lacking a mitochondrial signal peptide and subsequently located either
in the cytosol (FXN II) or in the nucleus (FXN III) [12].
2. Frataxin Gene Regulation
The interest in unraveling the molecular mechanisms associated with FRDA has led to advances
in certain aspects related to the regulation of the frataxin gene, although this information is still quite
incomplete. Two transcription start sites (TSS) are currently described in the FXN gene (Figure 1):
the first one (TSS1) is located at 221 base pairs upstream from the ATG [5], and the second TSS (TSS2)
is located at 62 bp upstream from the ATG (Figure 1); to date, it is still unknown which is the dominant
TSS [13].
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Figure 1. Regulatory elements in the FXN locus. Repetitive sequences, regulatory signals, and 
transcription factor binding sites present in the promoter region, exon 1 and the region surrounding 
GAA expansion within intron 1. ARE (Antioxidant Response Element); SINE (Short Interspersed 
Nuclear Element) family, which includes AluJb, AluY, Alu1, MIR and MIRb elements; MER1 
(primate-specific MEdium Reiteration 1); Inr (mammalian Initiator); DPE (Downstream Promoter 
Element); L2, a specific LINE (Long Interspersed Nuclear Element), E-box (Enhancer-box); p53RE (p53 
Responsive Element) and CpG (Cytosine-phosphoguanine) island. Transcription factor binding sites 
Nfr2 (or NFE2L2, Nuclear Factor (Erythroid-derived 2)-Like 2), SRF (Serum Response Factor), TFAP2 
(Transcription Factor AP-2) and EGR3 (Early Growth Response factor 3). TSS1 and TSS2 
(Transcription Start Site 1 and 2), 5’UTR (Untranslated Region 5’) and GAA triplet expansion 
((GAA)n). 
The promoter region also has certain peculiarities. The sequence between 1034 bp upstream and 
100 bp downstream from TSS1 plays the main role in the regulation of FXN, being considered as the 
minimal promoter. Although this region lacks TATA-box, it contains an Inr (mammalian Initiator) 24 
bp downstream from TSS1 and a Downstream Promoter Element (DPE) located 26 bp downstream 
from TSS1 (Figure 1). These Inr/DPE elements are considered core promoter regulatory elements, 
although previous studies indicate that they are not necessary for frataxin expression [14].  
Figure 1. Regulatory elements in the FXN locus. Repetitive sequences, regulatory signals, and transcription
factor binding sites present in the promot r region, exon 1 and the region surroundi g GAA expansion
within intron 1. ARE (Ant oxida t Response Element); SINE (Short Interspersed Nuclea Element)
family, which includes AluJb, AluY, Alu1, MIR and MIRb elements; MER1 (primate-specific MEdium
Reiteration 1); Inr (mammalian Initiator); DPE (Downstream Promoter Element); L2, a specific LINE
(Long Interspersed Nuclear Element), E-box (Enhancer-box); p53RE (p53 Responsive Element) and
CpG (Cytosine-phosphoguanine) island. Transcription factor binding sites Nfr2 (or NFE2L2, Nuclear
Factor (Erythroid-derived 2)-Like 2), SRF (Serum Response Factor), TFAP2 (Transcription Factor AP-2)
and EGR3 (Early Growth Response factor 3). TSS1 d TSS2 (Transcription Start Site 1 and 2), 5’UTR
(Untranslated Region 5’) and GAA triplet expansion ((GAA)n).
The promoter region also has certain peculiarities. The sequence between 1034 bp upstream and
100 bp downstream from TSS1 plays the main role in the regulation of FXN, being considered as the
minimal promoter. Although this region lacks TATA-box, it contains an Inr (mammalian Initiator) 24 bp
downstrea from TSS1 and a Downstream Promoter Element (DPE) located 26 bp downstrea from TSS1
(Figure 1). These Inr/DPE elements are consid red core promoter regul tory elements, although previous
studies indicate that they are not necessary for frataxin expression [14].
Despite the fact that frataxin is an essential gene, its promoter is not well-conserved in mammals,
mainly due to the insertion of retro-elements, which have been thought to be “evolutionary junk” until
recently [15]. However, there are already numerous studies suggesting that these elements could play
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an important role in the regulation of nearby genes [16]. MIR (Mammalian-wide Interspersed Repeat),
AluJb and AluY elements, which belong to the SINE (Short Interspersed Nuclear Element) family, have
been described in the promoter, as well as in a region 132 bases downstream from TSS1 that shares a
sequence with an L2 element, which is a type of LINE (Long Interspersed Nuclear Element) (Figure 1).
Although the exact functions of these elements are still unclear, their deletion has been observed to
significantly affect frataxin expression [14].
In the region between the start of intron 1 and the site where the expansion occurs, three repetitive
elements are intercalated: a MIRb element, a MER1 (primate-specific MEdium Reiteration 1) element,
and part of an Alu element, which is where the expansion of GAA repeats derives from [17] (Figure 1).
Regarding the transcription factors that regulate the expression of FXN, there are few data available to
date. Previous studies have identified a Serum Response Factor binding site (SRF, 91–110 bp downstream
from TSS1), which is important in neuronal development, an AP2 transcription factor binding site (TFAP2;
139–154 bp downstream from TSS1), involved in the development of the neural crest, and an Early
Growth Response factor 3 binding site (EGR3; 233–249 bp downstream from TSS2) [18]. The deletion
of these sequences significantly reduces the transcription of the gene, although the binding of these
transcription factors has not been confirmed [18]. The existence of an E-box (Enhancer-box) is crucial
to FXN expression and it binds to the MyoD and c-myc transcription factors [17]. A CCCTC binding
factor (CTCF) has been described between 154 and 173 bp downstream from TSS1 [19], which is a
chromatin insulator protein that prevents the spread of heterochromatin [20]. In addition, there is a
p53RE (p53 Responsive Element) 200 bp upstream from TSS1 (Figure 1), indicating that the transcription
of FXN is activated by p53 [21]. Finally, three important Antioxidant Response Elements (AREs) at 4.9,
5.6, and 16.7 kb upstream from TSS1 have also been described (Figure 1). These ARE elements direct
the expression of multiple anti-inflammatory genes, and are related to the presence of transcription
factor Nfr2 (or NFE2L2: Nuclear Factor (Erythroid-derived 2) -Like 2) [22], also shown to mediate in
anti-inflammatory processes [23,24].
3. Deciphering Regulatory Elements in the FXN Locus
A scientific field that has acquired special relevance in recent years is the study of epigenetics, which is
an essential mechanism in genome regulation [25]. Although the DNA sequence plays an essential role in
the regulation of gene expression, epigenetic mechanisms are crucial for their modulation [26]. DNA is
wrapped around eight proteins called histones (H2A, H2B, H3, and H4), forming a structure known
as nucleosome, the basic unit of chromatin [27]. Gene expression greatly depends on the accessibility
of chromatin, which dynamically switches between two states: euchromatin, (the loose/relaxed form
of chromatin), which may be active or inactive, and heterochromatin, defined as the condensed and
silenced state of chromatin. Post-translational modifications (PTMs) of histones such as phosphorylation,
methylation, acetylation, and ubiquitination [28] will affect nucleotide sequence reading [29].
In FRDA patients, FXN transcriptional deficiency initiation is the major cause of frataxin deficiency,
and it is related to the extent of repressive chromatin from the GAA expansion [13,30]. GAA expanded
repeats can adopt abnormal structures such as the triplex-based “sticky” DNA [31,32] and R-loops [33,34],
and result in the epigenetic silencing of a closely linked transgene [35,36]. The way in which the expanded
GAA triplet can cause such a decrease in the expression of this protein is still poorly understood,
although different findings suggest two non-exclusive hypotheses. The first hypothesis describes the
formation of an unusual non-B DNA structure or DNA/RNA hybrids that prevent the advance of RNA
polymerase II, based on the experiments of Ohshima and collaborators [37] (reviewed by [4]). The second
hypothesis proposes a “heterochromatinization” induced by the GAA-triplet expansion, based on the
studies of Saveliev and co-workers [35] (reviewed by [38]). There are different marks of heterochromatin
in the vicinity of the expansion, including histone deacetylation (H3K9ac, H3K14ac, and H4K5ac), histone
trimethylation (H3K9me3 and H3K27me3), and CpG DNA methylation [39–42]. These changes have seen
observed both upstream and downstream from the GAA expansion, although marks of heterochromatin
were more prominent immediately upstream, but still within intron 1 [30].
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MoststudiesonFXN generegulationhavebeenfocusedontheregionaroundtheminimalpromoter [14,19]
and the region of intron 1 in which GAA expansion causes FRDA [17]. However, numerous studies have
shown that both the intronic regions of a gene and the intergenic zones may play important roles in genomic
regulation [43]. Due to the increasing evidence suggesting that epigenetic changes could be involved in the
reduced levels of FXN transcripts [44,45], the aim of the present study was to obtain a more detailed view of
the whole genomic FXN locus from an epigenetic point of view. Thus, in this work, we used data generated
by ENCODE [46] and Roadmap consortia [47] to perform a bioinformatic study through data mining that
allowed us to identify new possible regulatory elements in the complete locus of the FXN gene.
3.1. Study of the FXN Locus in the Cell Lines Provided by the ENCODE Consortium
The objective of the ENCyclopedia Of DNA Elements (ENCODE) consortium is to identify all the
functional elements present in the human genome [46,48]. To do this, the consortium has recruited and
integrated a large variety of experimental data in a free access portal [49]. The interface developed by
the University of California Santa Cruz (https://genome-euro.ucsc.edu) is the main tool to access these
data [50,51].
As was previously mentioned, chromatin plays an important role in controlling DNA access and
specific histone marks are related to promoters, enhancers, transcribed regions, and silenced regions [52,53].
Combinations of these modifications can provide even more precise insight into chromatin state [54].
Within the ENCODE consortium, two research groups have developed different chromatin state
annotation algorithms: ChromHMM [55,56] and Segway [57,58]. Although with some differences, both
methods share many key features and employ closely related probabilistic models. As ChromHMM
offers more cell lines, we focused on this method for the analysis of the FXN locus, although none of
them have a neural origin [59]: B-lymphoblastoid cells (GM12876), embryonic stem cells (H1-hESC),
erythrocytic leukemia cells (K562), hepatocellular carcinoma cells (HepG2), umbilical vein endothelial
cells (HUVEC), mammary epithelial cells (HMEC), skeletal muscle myoblasts (HSMM), normal
epidermal keratinocytes (NHEK), and normal lung fibroblasts (NHLF).
The mapping of the different chromatin states was done using a ChIP-seq method with antibodies against
the following histone modifications: histone H3 lysine 4 methylation (H3K4me1), a mark predominantly
associated with enhancers; H3K4me2, associated with promoters and enhancers; H3K4me3, related to
promoters; H3K36me3 and H4K20me1, associated with transcribed regions; H3K27me3, associated with
Polycomb-repressed regions; histone 3 lysine 9 acetylation (H3K9ac) and H3K27ac, associated with active
regulatory regions; and CTCF, a sequence-specific insulator protein. The chromatin states were established
using a multivariate Hidden Markov Model (HMM) that models the combinatorial patterns of observed
modifications; the recurrent combinations of these marks define 15 chromatin states as repressed, poised,
and active promoters, strong and weak enhancers, putative insulators, transcribed regions, and large-scale
repressed and inactive domains [54].
The frataxin gene is composed of seven exons, spanning more than 80 kilobases. As we were
interested in analyzing not only the entire extension of the frataxin gene but also its upstream and
downstream regions, we focused on the chromosomal region between the end of the PRKACG gene,
located upstream from the 5′ end of the FXN gene, and the beginning of the TJP2 gene, located
downstream from the 3′ end (chromosome 9, 71629000–71736300 region) (Figure 2A). In order to
determine the most relevant regulatory zones in this genomic region, we only considered those areas
in which the epigenetic pattern shown by ENCODE is present in more than 40% of the analyzed cell
lines and whose extension exceeds 500 bp.
With these data, the bioinformatic analysis allowed us to identify nine possible regulatory regions
within the FXN genomic locus (Figure 2B and Table 1): two of them are located in the upstream region of
the gene (regions 1 and 2), one in the promoter zone (region 3), five in different introns (regions 4–8) and
one in the downstream region of the gene (region 9). Based on these results, the study reveals that intron
4, or more precisely the 3’ end of intron 4 (regions 6–9), might play an important role in gene regulation,
since these regions are associated with normal and strong enhancers (Figure 2B and Table 1).
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Figure 2. Chromatin states in the FXN geno ic locus based on ENCODE data. All data were collected
from the ENCODE database [46] and visuali i the University of California Santa C uz b owser
(https://genome-euro. csc.edu). (A) Frataxin ic locu span ing from the 3’end of the upstream
gene (PRKACG) to the 5’end of the downstream gene (TJP2) (chromosome 9, 71629000-71736300 region);
(B) Chromatin states across the FXN genomic locus, in which we can highlight nine regions: regions
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Table 1. Putative regulatory regions in the FXN genomic locus and associated chromatin state provided
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3.2. Study on Tissues and Primary Cultures Provided by the Roadmap Consortium
The US National Institutes of Health (NIH) established The Roadmap Epigenomics Program with
the goal f elucidating how epigen tic proc sses contribute to human biology and disease. They provide
a publicly accessible resource (http://epigenomegateway.wustl.edu/browser/roadmap) of epigenetic
maps in stem cells and ex-vivo tissues, including several human adult brain structures [47]. For the
realization of this analysis, different ty es of tissues were selected, including some of great interest in
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the study of Friedreich’s Ataxia, such as brain, muscle, pancreatic, and heart tissues. Regarding the
epigenetic marks, we focused on five histone modifications, already analyzed in the study carried out
with ENCODE data: H3K4me1, H3K4me3, H3K27me3, H3K27ac, and H3K36me3.
On the one hand, the different tissues studied show similar epigenetic patterns for some epigenetic
marks. For example, the H3K4me3 mark, associated with promoter zones, coincides in all the compared
tissues (Figure 3A), as well as the H3K36me3 mark, associated with active transcribed genes, although the
latter shows more intense signals at the initial part of introns 2 and 4, and along intron 3 (Figure 3B).
Finally, epigenetic mark H3K27me3, associated with heterochromatin zones, presents an intense signal in
the upstream region of the gene, also showing a similar pattern in all analyzed tissues (Figure 3C).Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 7 of 14 
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were collected from the Roadmap database [47] and visualiz d in its own browser (https://epigenomegateway.
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On the other hand, the H3K4me1 mark, related to enhancer regions, shows a more complex
epigenomic map, with common patterns among the different groups of tissues analyzed, alongside
regions showing specific patterns for each group (Figure 4A). According to the values provided by
the Roadmap Consortium, we can differentiate 20 different regions classified as "weak" (signal score
below 7.5), "intermediate" (between 7.5 and 10) or "strong" (greater than 10) enhancers (Table 2). In this
sense, the region between the end of intron 4 and the downstream region close to FXN is of special
interest, since in this region the signal of epigenetic mark H3K4me1 is weak in brain and muscle
tissues, practically absent in pancreatic and cardiac tissues, and strong in the rest of the analyzed
tissues (Figure 4A). Taking into account that brain and muscle tissues are especially affected in FRDA,
and that patients with this disease have cardiac muscle atrophies and are prone to developing diabetes,
these findings may suggest a direct relationship between the absence of enhancer sequences in this
region and their predisposition to be affected in FRDA.
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Table 2. Intensity of the H3K4me1 epigenetic mark across the studied region: “weak” (<7.5; white), 
“intermediate” (7.5–10; light grey) or “strong” signal (> 10; dark grey). Abbreviations: Down, 
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Figure 4. Epigenetic marks of enhancer regions in tissues provided by Roadmap. All data were collected
from the Roadmap database [47] and visualized in its own browser (https://epigenomegateway.wustl.edu/
browser/roadmap). (A) H3K4me1 mark is related to enhancer regions; (B) H3K27ac mark is associated
with strong enhancers. Tissues are organized in three groups: brain, muscle, and other tissues. Both marks
(H3K4me1 and H3K27ac) show tissue-specific patterns, highlighting the region between the 3’end zone of
intron 4 and the downstream region closest to the FXN gene, where H3K4me1 and H3K27ac signals are
almost inexistent in muscle and brain tissues, whereas the remaining tissues present high intensity (region
in brackets).
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Table 2. Intensityof theH3K4me1epigeneticmarkacross thestudiedregion: “weak”(<7.5; white), “intermediate”
(7.5–10; light grey) or “strong” signal (> 10; dark grey). Abbreviations: Down, Downstream region; Ix,
Intron x; ORF, Open Reading Frame; Up, Upstream region.
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Up 
1 71630400 71632000 12.14 13.50 9.67 
2 71634700 71636000 5.71 3.75 10.17 
3 71638300 71639600 8.43 5.50 10.50 
4 71642100 71643100 13.29 9.25 12.17 
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O
R
F 
I1 
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I3 
9 71668400 71670400 12.29 11.50 8.67 
10 71678600 71681700 9.71 8.00 9.33 
I4 
11 71683300 71686300 5.00 4.00 12.67 
12 71690700 71691900 5.29 11.50 5.33
13 71693000 71694500 16.71 15.50 12.67 
14 71697600 71698700 12.50 6.50 9.67 
15 71700300 71702400 11.86 8.50 15.50 
16 71703700 71705900 8.71 6.50 13.00 
17 71708600 71709200 3.86 2.50 21.33 
18 71713500 71715400 5.57 4.00 13.17 
Down 
19 71718800 71721000 4.71 4.00 14.00 
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This view is reinforced with the epigenetic map shown by H3K27ac modification, which is an
indicator of “strong” enhancers. Similarly, although more clearly, the zone of the FXN genomic locus
with the most intense signal coincides with the enhancer regions that were previously highlighted
(end of intron 4 and downstream region close to FXN) and in the same tissue types (Figure 4B).
Finally, we also analyzed the H3K4me1 and H3K27ac marks in the primary cultures provided by the
Roadmap Consortium: peripheral blood mononuclear cells, penile foreskin melanocytes and keratinocytes,
bone marrow-derived mesenchymal stem cells, and ganglionic eminence-derived neurospheres. In the
same way, as already indicated for the different tissues analyzed above, we can clearly distinguish two
different patterns in the region near the end of intron 4, where primary cultures of neural origin present a
weak signal in both H3K4me1 (enhancer ) and H3K27ac (strong enh cers), in co trast to th rest of the
cult e , wh re a strong signal can b observed ( ata not shown).
4. Future Perspectives
Given that over 95% of the human genome reveals no protein-coding information, studies are
forced to shift the focus from genomes to epigenomes, with the aim of explaining how the complex
diversity of human cells may be caused only by a limited number of genes. Using already published
information, we described how different types of human cells and tissues present a different regulatory
pattern, including regions inside the frataxin gene and in the upstream and downstream regions of the
gene. The region of intron 4 is of particular relevance, due to the differences observed between affected
cells and tissues from FRDA patients compared to other tissues that are not affected by the disease.
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However, it is important to remark that, despite having access to epigenetic studies in brain tissues [47],
there are no highly significant data in the most affected tissues in FRDA, such as the cerebellum or the
spinal cord.
The findings shown in this study highlight the essential role of certain intronic regions in gene
regulation [60,61] and thus support the use of vectors capable of harboring large DNA fragments (whole
genomic loci) in gene therapy trials. Vectors encoding FXN cDNA may result in protein overexpression
in the heart and cerebellum, as well as in off-target organs, such as the liver, which has been associated
with significant cardiotoxicity [62]. Another study of FXN overexpression in cultured human cells also
shows that the levels of FXN must be tightly regulated and fine-tuned, with any imbalance leading to
oxidative stress and cytotoxicity [63]. In contrast, using Yeast and Bacteria Artificial Chromosomes
(YACs and BACs, respectively), it has been shown that large genomic fragments allow tissue-specific
expression at physiological levels [64]. Our laboratory has also conducted various studies of FRDA
gene therapy using vectors based on HSV-1; this virus was selected for its large storage capacity,
which allows the complete packaging of the human frataxin gene. With this approach, we observed a
recovery of frataxin levels and a rescue against oxidative stress in fibroblasts of FRDA patients [65].
In addition, it has also been found that the use of a herpesviral vector bearing this BAC allows the
long-term expression of FXN in vivo [66]. On the other hand, the different functions of frataxin remain
a subject of controversy. A number of different forms of the protein have been described with different
specific functions [67,68], and three isoforms of the frataxin protein have also been described [12],
with specific cellular locations for each of them. Our laboratory also demonstrated that the BAC
vector with the frataxin genomic locus packaged in HSV-1 vectors was able to produce all the different
frataxin isoforms described in vitro, both in several neural cultures, including cells derived from the
patient, and after injections into mouse cerebellum in vivo [69]. Furthermore, we have also optimized
the HSV-1 vector generation process, bringing this technique closer to its wide clinical application [70].
Therefore, based on previous evidence and on the results obtained in this bioinformatic study,
vectors with complete genomic loci are a promising candidate for gene therapy in FRDA patients, since
they contain all the regulatory elements necessary for the physiological expression of frataxin.
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